[1] [3] Marketed under the brand names Mounjaro (for diabetes) and Zepbound (for weight management), tirzepatide represents the first dual incretin receptor agonist available in clinical practice
For example, semaglutide 2.4 mg appears pharmacodynamically comparable to tirzepatide 10 mg, while semaglutide 7.2 mg approximates tirzepatide 15 mg
In patients with type 2 diabetes mellitus, treatment with semaglutide injection 1 mg resulted in reductions in glucose in terms of absolute change from baseline and relative reduction compared to placebo of 29 mg/dL (22%) for fasting glucose, 74 mg/dL (36%) for 2-hour postprandial glucose and 30 mg/dL (22%) for mean 24-hour glucose concentration
You can also purchase the subscription to get free shipping and extra savings
Actually, at the time of this recording, there are 223 confirmed cases with children under 18, making up about 78% of these cases